A carregar...
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
BACKGROUND: We conducted a phase I dose escalation study to evaluate the safety and immunologic response to peptide immunomodulatory vaccines GL-0810 (HPV16) and GL-0817 (MAGE-A3) in HPV16 and MAGE-A3-positive RM–SCCHN patients, respectively. METHODS: Three dose levels (500, 1,000, and 1,500 µg) of...
Na minha lista:
Publicado no: | Cancer Immunol Immunother |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Springer Berlin Heidelberg
2014
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4381442/ https://ncbi.nlm.nih.gov/pubmed/25537079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-014-1640-x |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|